ARCA biopharma - Scientific Publications

Business Development

Newsroom

Scientific Publications

Quality of Life and Prognosis in Heart Failure: Results of the Beta-Blocker Evaluation of Survival Trial (BEST)
Tate CW, et. al.
Journal of Cardiac Failure, 2007

A Polymorphism Within a Conserved β1-adrenergic Receptor Motif Alters Cardiac Function and β-blocker Response in Human Heart Failure
Liggett S, et. al.
The National Academy of Sciences, 2006

Impact of Nonfatal Myocardial Infarction on Outcomes in Patients With Advanced Heart Failure and the Effect of Bucindolol Therapy
O’Connor C, et. al.
The American Journal of Cardiology, 2005

Effect of Baseline or Changes in Adrenergic Activity on Clinical Outcomes in the Beta-Blocker Evaluation of Survival Trial (BEST)
Bristow M, et. al.
Circulation, 2004

β1 – Adrenergic Receptor Polymorphisms Confer Differential Function and Predisposition to Heart Failure
Mialet Perez, et. al.
Nature Medicine, 2003

A Comparative Analysis of the Results from 4 Trials of β-Blocker Therapy for Heart Failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS
Domanski M, et. al.
Journal of Cardiac Failure, 2003

The Effect of Diabetes on Outcomes of Patients With Advanced Heart Failure in the BEST Trial
Domanski M, et. al.
Journal of the American College of Cardiology, 2003

Synergistic Polymorphisms of β1 and α2c – Adrenergic Receptors and the Risk of Congestive Heart Failure
Small, et. al.
New England Journal of Medicine, 2002

A Trial of the Beta-Blocker Bucindolol in Patients with Advanced Chronic Heart Failure
The BEST Manuscript Writing Committee
New England Journal of Medicine, 2001

DISCLAIMER

Bucindolol is currently an investigational compound that has not been approved by the FDA for use in the United States. ARCA biopharma has submitted a new drug application to the FDA for bucindolol. The information on this page is for health care professionals only.

ARCA ©2012 ARCA biopharma | Home | Site Map | Legal Disclaimer